Following on from another successful year of growth in 2018, the Lymphoma Hub continues to disseminate the latest congress news and clinical updates in lymphoma and chronic lymphocytic leukemia (CLL).
Guided by an international Steering Committee of world experts in lymphoma, the Lymphoma Hub is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. With an ever-expanding social media presence, the lymphoma hub engages with the global community on all major social media networks, providing a finger on the pulse of everyday, real-world clinical practice.
The Lymphoma Hub is designed to deliver upon an unmet need for targeted medical updates, to help treatment teams involved in lymphoma and CLL care make informed therapeutic decisions.
The Lymphoma Hub showcases unbiased and credible evidence-based literature, drug approvals, case studies, international congress coverage and expert opinions, delivered by Scientific Education Support (SES).
SES love nothing more than building communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.
This year, the Lymphoma Hub is proud to announce Kite a Gilead company, as new silver supporter of the Lymphoma Hub. The Lymphoma Hub would like to thank our platinum supporter Celgene, silver supporters AstraZeneca
and Janssen Oncology, and bronze supporters Roche and Nordic Nanovector for their continued support.
For further information on the Lymphoma Hub, please visit: www.lymphomahub.com. For media enquiries, or to explore collaboration opportunities, please contact: firstname.lastname@example.org.
Press release distributed by Pressat on behalf of Scientific Education Support (SES), on Friday 31 May, 2019. For more information subscribe and follow https://pressat.co.uk/